Skip to main content

and
  1. No Access

    Article

    Erythropoietin/Erythropoietin-receptor system as an angiogenic factor in chemically induced murine hepatic tumors

    To clarify the role of erythropoietin (Epo) in hepatic tumor angiogenesis, expression of Epo and its receptor (Epo-R) and content of Epo were investigated in murine chemically induced hepatic tumors.

    Kiyoshi Nakamatsu, Yasumasa Nishimura in International Journal of Clinical Oncology (2004)

  2. No Access

    Article

    Comparison of outcomes between overlap** structure-based and non-overlap** structure-based optimization for simultaneous integrated boost IMRT for malignant gliomas

    Intensity-modulated radiotherapy (IMRT) can deliver different doses to two target volumes with high conformity. The purpose of the present study was to compare outcomes provided by two different optimization m...

    Minoru Suzuki, Kiyoshi Nakamatsu in International Journal of Clinical Oncology (2004)

  3. No Access

    Article

    Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy

    The aim of this article is to report the treatment outcomes, toxicities, and dosimetric feasibility of our simultaneous-boost intensity-modulated radiotherapy (SIB-IMRT) protocol.

    Kiyoshi Nakamatsu, Minoru Suzuki in International Journal of Clinical Oncology (2008)

  4. No Access

    Article

    Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study

    The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial 125I implanta...

    Nobutaka Shimizu, Takafumi Minami, Koichi Sugimoto in World Journal of Urology (2014)

  5. No Access

    Article

    Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer

    The clinical results of definitive-dose preoperative chemoradiotherapy (CRT) of 50 Gy/25 fractions/5 weeks for unresectable esophageal cancer were analyzed.

    Kazuki Ishikawa, Kiyoshi Nakamatsu in International Journal of Clinical Oncology (2015)

  6. No Access

    Article

    Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers

    Clinical results of computed tomography (CT) simulations and [18F]-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET)/CT simulations were compared retrospectively.

    Tomohiro Matsuura, Yasumasa Nishimura in International Journal of Clinical Oncology (2017)

  7. Article

    Open Access

    Evaluation of multiple institutions’ models for knowledge-based planning of volumetric modulated arc therapy (VMAT) for prostate cancer

    The aim of this study was to evaluate the performance of a commercial knowledge-based planning system, in volumetric modulated arc therapy for prostate cancer at multiple radiation therapy departments.

    Yoshihiro Ueda, Jun-ichi Fukunaga, Tatsuya Kamima, Yumiko Adachi in Radiation Oncology (2018)

  8. Article

    Open Access

    Mechanical performance of a commercial knowledge-based VMAT planning for prostate cancer

    This study clarified the mechanical performance of volumetric modulated arc therapy (VMAT) plans for prostate cancer generated with a commercial knowledge-based treatment planning (KBP) and whether KBP system ...

    Mikoto Tamura, Hajime Monzen, Kenji Matsumoto, Kazuki Kubo in Radiation Oncology (2018)

  9. No Access

    Article

    Definitive chemoradiotherapy for anal canal cancer: single-center experience

    Chemoradiotherapy (CRT) is a standard treatment for anal canal cancer although many patients with anal canal cancer undergo surgery in Japan. The efficacy of CRT for anal canal cancer was evaluated retrospecti...

    Izumi Tachibana, Yasumasa Nishimura in International Journal of Clinical Oncology (2018)

  10. No Access

    Article

    Stereotactic body radiotherapy in patients with chronic obstructive pulmonary disease and interstitial pneumonia: a review

    Stereotactic body radiation therapy (SBRT) can yield excellent local tumor control, as well as survival benefit comparable to that of surgery for early-stage lung cancer. However, in terms of toxicity, SBRT mi...

    Hiroshi Doi, Kiyoshi Nakamatsu in International Journal of Clinical Oncology (2019)

  11. No Access

    Article

    Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer

    This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC).

    Hideyuki Harada, Shota Omori, Keita Mori in International Journal of Clinical Oncology (2022)

  12. No Access

    Article

    External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy

    To investigate the risk of bladder cancer (BCa) in patients treated with brachytherapy for prostate cancer (PCa).

    Takafumi Minami, Kazutoshi Fujita, Mamoru Hashimoto in World Journal of Urology (2023)

  13. No Access

    Article

    Difference in failure patterns after stereotactic body radiotherapy for lung cancer according to clinical T stage based on 4D computed tomography

    Stereotactic body radiotherapy (SBRT) is a treatment option for early-stage lung cancer. We aimed to examine the differences in failure patterns after SBRT according to the clinical T stage.

    Takaya Inagaki, Hiroshi Doi MD PhD, Masahiro Inada in Strahlentherapie und Onkologie (2023)

  14. No Access

    Article

    Clinical course of longer than five years after definitive radiotherapy for nasopharyngeal carcinoma

    This study aimed to reveal the long-term outcomes and late toxicities (> 5 years) after definitive intensity-modulated radiation therapy (IMRT) in patients with nasopharyngeal carcinoma (NPC).

    Hiroshi Doi, Aritoshi Ri, Masahiro Inada in International Journal of Clinical Oncology (2023)